23andMe
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
23andMe was a consumer genetics company founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. It pioneered direct-to-consumer DNA testing, selling mail-in saliva kits for under $200 that reported on ancestry and health-related genetic traits. At its peak the company had sold more than 12 million kits and reached a valuation of about $6 billion after going public through a SPAC merger in 2021. It also built a drug-discovery research business on top of its genetic database.
02 / 23andMe FAILURE REASONS
Failure reasons
23andMe never turned a profit: the one-time DNA kit was a weak repeat-purchase business, and its expensive pivot into therapeutics burned cash without producing approved drugs. A 2023 data breach exposed the personal information of 6.9 million users, shattering customer trust and triggering a $30 million class-action settlement. The share price fell more than 95% from its peak, and governance collapsed when all seven independent directors resigned in September 2024 over disagreements with CEO Anne Wojcicki's push to take the company private. With sales falling and cash running out, the company filed for Chapter 11 bankruptcy in March 2025.
03 / EVENT HISTORY
Events in the structured record
- Founded
Anne Wojcicki, Linda Avey, and Paul Cusenza found 23andMe to sell direct-to-consumer DNA testing kits.
- SPAC listing at $6 billion valuation
The company goes public in June 2021 through a SPAC merger, reaching a valuation of more than $6 billion, but never turns a profit.
- Data breach
Hackers exploit reused passwords to access the personal information of 6.9 million users; the company later agrees to a $30 million class-action settlement.
- Board collapse and layoffs
All seven independent directors resign in September 2024 after rejecting CEO Anne Wojcicki's take-private proposal; the company lays off 40% of its workforce in November.
- Bankruptcy and asset sale
23andMe files for Chapter 11 protection in March 2025; Wojcicki resigns as CEO. In June 2025 the bankruptcy court approves the sale of substantially all assets - including the Personal Genome Service, research operations, and Lemonaid Health - to TTAM Research Institute, Wojcicki's nonprofit, for $305 million, beating Regeneron Pharmaceuticals' $256 million bid.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
23andMe filed for Chapter 11 bankruptcy protection in March 2025 in the US Bankruptcy Court for the Eastern District of Missouri, securing $35 million in debtor-in-possession financing from JMB Capital Partners.
- 02
A court-supervised auction of substantially all assets followed; in June 2025 the court approved the sale to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, for $305 million - beating Regeneron Pharmaceuticals' $256 million bid. The deal included the Personal Genome Service, research operations, and the Lemonaid Health telehealth subsidiary, with TTAM relaunching the company as a nonprofit.
- 03
The company voluntarily delisted from Nasdaq and deregistered with the SEC.